Attovia Therapeutics (ATTO) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on next-generation biotherapeutics for immune-mediated diseases using the ATTOBODY platform.

• Lead candidates target validated pathways in chronic pruritic and inflammatory diseases, with a pipeline including ATTO-1310 (IL-31 inhibitor), ATTO-2306 (IL-13/IL-31 bispecific), and ATTO-1091 (TL1A/IL-23/integrin α4β7 trispecific).

• All candidates are internally discovered using a proprietary, high-throughput platform licensed from Alamar Biosciences.

• Strategy includes expanding the pipeline, leveraging strategic collaborations, and focusing on infrequent subcutaneous dosing for patient convenience.

Financial performance and metrics

• No product revenue to date; revenue of $1.4 million in 2025 from a collaboration agreement.

• Net losses: $39.8 million (2024), $60.6 million (2025), $18.7 million (Q1 2026); accumulated deficit of $129.7 million as of March 31, 2026.

• Cash, cash equivalents, and marketable securities: $132.6 million as of March 31, 2026.

• Pro forma net loss per share (2025): $(2.37); pro forma as adjusted cash after IPO: $316.3 million.

Use of proceeds and capital allocation

• Estimated net proceeds of $182.4 million (or $210.3 million if over-allotment is exercised) at $16.00 per share.

• Proceeds to fund clinical development of ATTO-1310 (through Phase 2), ATTO-2306 (through Phase 2), and ATTO-1091 (through Phase 1), as well as other R&D, working capital, and general corporate purposes.

• Funds expected to support operations into 2029, but additional capital will be needed to complete development and commercialization.